Synopsis
Synopsis
0
VMF
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz


1. 53 32c
2. 53-32c
3. 5332c
4. Hydrochloride, Ticlopidine
5. Ticlid
6. Ticlodix
7. Ticlodone
8. Ticlopidine
1. 53885-35-1
2. Ticlopidine Hcl
3. Ticlid
4. Ticlodix
5. Ticlodone
6. Panaldine
7. Tiklid
8. 5-(2-chlorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine Hydrochloride
9. Ipaton
10. Ticlopidine (hydrochloride)
11. 53-32c
12. 4-c-32
13. Nsc-759165
14. Mls000083578
15. A1l4914fmf
16. Tiklyd
17. Thieno(3,2-c)pyridine, 5-((2-chlorophenyl)methyl)-4,5,6,7-tetrahydro-, Hydrochloride
18. Smr000048468
19. 5-[(2-chlorophenyl)methyl]-4h,5h,6h,7h-thieno[3,2-c]pyridine Hydrochloride
20. Chebi:9589
21. 5-[(2-chlorophenyl)methyl]-6,7-dihydro-4h-thieno[3,2-c]pyridine;hydrochloride
22. Ticlopidinehydrochloride
23. Einecs 258-837-4
24. Unii-a1l4914fmf
25. Aplaket
26. Sr-01000003130
27. Ticlopidine, Hcl
28. Prestwick_502
29. Mfcd00079606
30. Ticlid (tn)
31. 5-[(2-chlorophenyl)methyl]-4,5,6,7-tetrahydrothieno[3,2-c]pyridine Hydrochloride
32. Ticlopidine Hydrochloride [usan:usp:jan]
33. Opera_id_1799
34. 5-(o-chlorobenzyl)-4,5,6,7-tetrahydrothieno-(3,2-c)pyridine Hydrochloride
35. Chembl1717
36. Schembl33596
37. Mls000028579
38. Mls001401394
39. Ticlopidine Hydrochloride,(s)
40. Hy-b0153a
41. Dtxsid80202141
42. Hms1568i15
43. Pharmakon1600-01505677
44. Bcp23429
45. Nsc759165
46. S1984
47. Ticlopidine Hydrochloride [mi]
48. 5-(o-chlorobenzyl)-4,5,6,7-tetrahydrothieno(3,2-c)pyridinium Chloride
49. Akos015905580
50. Ticlopidine Hydrochloride (jp17/usp)
51. Ac-8973
52. Ccg-101023
53. Cs-1985
54. Nc00273
55. Nsc 759165
56. Ticlopidine Hydrochloride [jan]
57. Thieno(3,2-c)pyridine, 4,5,6,7-tetrahydro-5-(o-chlorobenzyl)-, Hydrochloride
58. Ticlopidine Hydrochloride [usan]
59. Ticlopidine Hydrochloride [mart.]
60. Ticlopidine Hydrochloride [vandf]
61. As-10890
62. Bt164472
63. Ticlopidine Hydrochloride [usp-rs]
64. Ticlopidine Hydrochloride [who-dd]
65. Bcp0726000288
66. Ft-0630664
67. T3110
68. D01028
69. I11518
70. Ticlopidine Hydrochloride [ep Impurity]
71. Ticlopidine Hydrochloride [ep Monograph]
72. Ticlopidine Hydrochloride [orange Book]
73. Ticlopidine Hydrochloride [usp Monograph]
74. 885t351
75. Sr-01000003130-6
76. W-105699
77. Q27108439
78. 5-(2-chlorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine Hcl
79. Ticlopidine Hydrochloride, Analytical Standard, For Drug Analysis
80. 5-(2-chloro-benzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine Hydrochloride
81. 5-(2-chlorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridinehydrochloride
82. Ticlopidine Hydrochloride, European Pharmacopoeia (ep) Reference Standard
83. 5-(2-chloro-benzyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridine Hydrochloride
84. 5-(o-chlorobenzyl)-4,5,6,7-tetrahydrothieno(3,2-c)pyridine Hydrochloride
85. Ticlopidine Hydrochloride, United States Pharmacopeia (usp) Reference Standard
| Molecular Weight | 300.2 g/mol |
|---|---|
| Molecular Formula | C14H15Cl2NS |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 2 |
| Rotatable Bond Count | 2 |
| Exact Mass | 299.0302260 g/mol |
| Monoisotopic Mass | 299.0302260 g/mol |
| Topological Polar Surface Area | 31.5 Ų |
| Heavy Atom Count | 18 |
| Formal Charge | 0 |
| Complexity | 261 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
| 1 of 2 | |
|---|---|
| Drug Name | Ticlopidine hydrochloride |
| Drug Label | Ticlopidine hydrochloride is a platelet aggregation inhibitor. Chemically it is 5-[(2-chlorophenyl)methyl]-4,5,6,7-tetrahydrothieno [3,2-c] pyridine hydrochloride. The structural formula is:C14H14ClNS HCl M.W. 300.25Ticlopidine hydrochloride is a... |
| Active Ingredient | Ticlopidine hydrochloride |
| Dosage Form | Tablet |
| Route | Oral |
| Strength | 250mg |
| Market Status | Prescription |
| Company | Teva; Apotex; Sun Pharm Inds |
| 2 of 2 | |
|---|---|
| Drug Name | Ticlopidine hydrochloride |
| Drug Label | Ticlopidine hydrochloride is a platelet aggregation inhibitor. Chemically it is 5-[(2-chlorophenyl)methyl]-4,5,6,7-tetrahydrothieno [3,2-c] pyridine hydrochloride. The structural formula is:C14H14ClNS HCl M.W. 300.25Ticlopidine hydrochloride is a... |
| Active Ingredient | Ticlopidine hydrochloride |
| Dosage Form | Tablet |
| Route | Oral |
| Strength | 250mg |
| Market Status | Prescription |
| Company | Teva; Apotex; Sun Pharm Inds |
Platelet Aggregation Inhibitors
Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system. (See all compounds classified as Platelet Aggregation Inhibitors.)
Fibrinolytic Agents
Fibrinolysin or agents that convert plasminogen to FIBRINOLYSIN. (See all compounds classified as Fibrinolytic Agents.)
Cytochrome P-450 CYP2C19 Inhibitors
Drugs and compounds which inhibit or antagonize the biosynthesis or actions of CYTOCHROME P-450 CYP2C19. (See all compounds classified as Cytochrome P-450 CYP2C19 Inhibitors.)
Purinergic P2Y Receptor Antagonists
Compounds that bind to and block the stimulation of PURINERGIC P2Y RECEPTORS. Included under this heading are antagonists for specific P2Y receptor subtypes. (See all compounds classified as Purinergic P2Y Receptor Antagonists.)

API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us
Related Excipient Companies
Excipients by Applications
Global Sales Information
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
46
PharmaCompass offers a list of Ticlopidine API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Ticlopidine manufacturer or Ticlopidine supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Ticlopidine manufacturer or Ticlopidine supplier.
PharmaCompass also assists you with knowing the Ticlopidine API Price utilized in the formulation of products. Ticlopidine API Price is not always fixed or binding as the Ticlopidine Price is obtained through a variety of data sources. The Ticlopidine Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A AC-10987 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of AC-10987, including repackagers and relabelers. The FDA regulates AC-10987 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. AC-10987 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of AC-10987 manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A AC-10987 supplier is an individual or a company that provides AC-10987 active pharmaceutical ingredient (API) or AC-10987 finished formulations upon request. The AC-10987 suppliers may include AC-10987 API manufacturers, exporters, distributors and traders.
click here to find a list of AC-10987 suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A AC-10987 DMF (Drug Master File) is a document detailing the whole manufacturing process of AC-10987 active pharmaceutical ingredient (API) in detail. Different forms of AC-10987 DMFs exist exist since differing nations have different regulations, such as AC-10987 USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A AC-10987 DMF submitted to regulatory agencies in the US is known as a USDMF. AC-10987 USDMF includes data on AC-10987's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The AC-10987 USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of AC-10987 suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The AC-10987 Drug Master File in Japan (AC-10987 JDMF) empowers AC-10987 API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the AC-10987 JDMF during the approval evaluation for pharmaceutical products. At the time of AC-10987 JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of AC-10987 suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a AC-10987 Drug Master File in Korea (AC-10987 KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of AC-10987. The MFDS reviews the AC-10987 KDMF as part of the drug registration process and uses the information provided in the AC-10987 KDMF to evaluate the safety and efficacy of the drug.
After submitting a AC-10987 KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their AC-10987 API can apply through the Korea Drug Master File (KDMF).
click here to find a list of AC-10987 suppliers with KDMF on PharmaCompass.
A AC-10987 CEP of the European Pharmacopoeia monograph is often referred to as a AC-10987 Certificate of Suitability (COS). The purpose of a AC-10987 CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of AC-10987 EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of AC-10987 to their clients by showing that a AC-10987 CEP has been issued for it. The manufacturer submits a AC-10987 CEP (COS) as part of the market authorization procedure, and it takes on the role of a AC-10987 CEP holder for the record. Additionally, the data presented in the AC-10987 CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the AC-10987 DMF.
A AC-10987 CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. AC-10987 CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of AC-10987 suppliers with CEP (COS) on PharmaCompass.
A AC-10987 written confirmation (AC-10987 WC) is an official document issued by a regulatory agency to a AC-10987 manufacturer, verifying that the manufacturing facility of a AC-10987 active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting AC-10987 APIs or AC-10987 finished pharmaceutical products to another nation, regulatory agencies frequently require a AC-10987 WC (written confirmation) as part of the regulatory process.
click here to find a list of AC-10987 suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing AC-10987 as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for AC-10987 API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture AC-10987 as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain AC-10987 and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a AC-10987 NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of AC-10987 suppliers with NDC on PharmaCompass.
AC-10987 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of AC-10987 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right AC-10987 GMP manufacturer or AC-10987 GMP API supplier for your needs.
A AC-10987 CoA (Certificate of Analysis) is a formal document that attests to AC-10987's compliance with AC-10987 specifications and serves as a tool for batch-level quality control.
AC-10987 CoA mostly includes findings from lab analyses of a specific batch. For each AC-10987 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
AC-10987 may be tested according to a variety of international standards, such as European Pharmacopoeia (AC-10987 EP), AC-10987 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (AC-10987 USP).